Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular CarcinomaGiuseppe Cabibbo, Calogero Cammà, Ciro Celsa et al.|Cancers|2020Cited by 34